Market News & Trends
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid & Large-Scale Proteomics
Seer recently announced it has signed a non-exclusive commercial agreement with Thermo Fisher Scientific for Seer to offer Thermo Fisher’s Orbitrap Eclipse Tribid and Orbitrap…
First Patient Dosed in Pilot Study for Acute Musculoskeletal Pain
Vitalis LLC recently announced the dosing of the first patient in a pilot study evaluating safety and preliminary analgesic efficacy of VTS-K in patients with…
DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19
DalCor Pharmaceuticals recently announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19. The main…
Cara Initiates Phase 2 Trial of Oral Treatment for Pruritus in Patients with Notalgia Paresthetica
Cara Therapeutics, Inc. recently announced the initiation of a Phase 2 trial of Oral KORSUVA (difelikefalin) for the treatment of moderate-to-severe pruritus in patients suffering…
SIRION Biotech GmbH Licensed LentiBOOST™ Transduction Technology to Cellectis
Through this recent license agreement, SIRION Biotech GmbH has granted Cellectis non-exclusive right under its proprietary lentiviral transduction….
Servier & X-Chem Announce Drug Discovery Collaboration
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
Kite & Oxford BioTherapeutics Establish Cell Therapy Research Collaboration
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….
Argenx & Zai Lab Announce Strategic Collaboration
Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….
Gerresheimer Builds New Production Plant for Plastic Containers in India
With Triveni Polymers Pvt. Ltd. in Kundli, Gerresheimer has already been well positioned in India for many years. A second production plant in Kosamba (Gujarat)…
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion
Catalyst Pharmaceuticals, Inc. recently announced an expansion in its strategic priorities related to portfolio planning and research and development. Catalyst also provided preliminary net revenues…
WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA
STA Pharmaceutical, a WuXi AppTec Company (WuXi STA), recently announced their partner Innocare has received approval by the National Medical Products Administration of China (NMPA)…
Silo Pharma Inc. Receives $1 Million in Up Front Licensing Deal
Silo Pharma, Inc. recently announced it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the…
EMA Recommends COVID-19 Vaccine Moderna for Authorization in the EU
The EMA has recently recommended granting a conditional marketing authorization for COVID-19 Vaccine Moderna to prevent coronavirus disease 2019 (COVID-19) in people from 18 years…
Apollomics & GlycoMimetics Granted Breakthrough Therapy Designation
Apollomics, Inc. and GlycoMimetics recently announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for…
ViGeneron Signs Global Development & Commercialization Agreement With Biogen
ViGeneron GmbH recently announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat….
Radius Health Announces Commercial Agreement With Paladin Labs
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….
University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Arch Biopartners Inc. RECENTLY announced the University of Calgary Cumming School of Medicine has joined the Phase 2 trial of its lead drug LSALT peptide (Metablok), targeting the prevention….
Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100 Million
Rhythm Pharmaceuticals, Inc. recently announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million.…
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Ocuphire Pharma, Inc. recently announced the initiation of patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety…
PHASTAR Announces Investment by Charterhouse Capital Partners
PHASTAR recently announced an investment made by Charterhouse Capital Partners LLP that will support PHASTAR’s growth in biometrics and geographic expansion. Charterhouse is making its…
